Teva Pharmaceutical Industries Limited (TEVA) Stock Analysis
Is TEVA a good investment?
Teva Pharmaceutical Industries Limited (TEVA) has a Plutrex AI rating of 58.5/100 as of August 22, 2026, indicating a Hold consensus. The stock is not classified as halal-compliant. Key strength: FCF of $2.22 billion (~5.9% FCF yield at current market cap) is the most underappreciated asset — GAAP earnings of ~$0.60/share dramatically understate cash economics due to non-cash Actavis amortization; this FCF funds aggressive debt reduction (leverage ratio now below 3x EBITDA, targeting 2x by 2027) and demonstrates the business generates real cash despite depressed reported earnings. Main concern: Valuation is the primary risk and has WORSENED marginally: P/E of 61.9x is now 117.1% above the industry average of 28.5x (up from 116.9% prior), PEG of 2.18 is 62.9% above peers at 1.34 (up from 62.4%), yet 5-year EPS CAGR of 5.5% remains 55.3% BELOW the industry average of 12.30% — Teva is the most expensive stock in the peer group relative to its long-term earnings power; if the branded pivot disappoints and the multiple compresses from 61x to 25x (still above industry average), the stock falls to approximately $15, a 60% loss from current levels; upside to analyst target has narrowed from 15.3% to 13.5% as the stock rose 1.6%.
Investment Summary
Teva Pharmaceutical (TEVA) at $37.34 remains a Hold — a genuine turnaround story that the market has already priced aggressively, leaving insufficient margin of safety at current levels. The core tension: Teva's 'Pivot to Growth' strategy is executing (leverage ratio below 3x EBITDA, specialty revenue scaling, FDA Priority Review granted for ecopipam in pediatric Tourette syndrome), but the stock's P/E of 61.9x — 117% above the industry average of 28.5x — prices in near-perfection for a business with only 5.5% long-term EPS CAGR. FCF of $2.22 billion (~5.9% yield on current market cap of ~$37.5B) is the most compelling fundamental anchor, but the PEG of 2.18 versus the industry average of 1.34 confirms growth-adjusted overvaluation. News sentiment of 89.1/100 is the strongest it has been, with 10 of 13 articles positive, reflecting genuine operational momentum. However, the stock has risen another 1.6% from $36.77 to $37.34 since the prior report, further compressing the already-thin upside to the $42.38 analyst target (now only 13.5%). The risk/reward at current price remains unfavorable: 13.5% upside to target versus potential 59% downside if the 61x multiple compresses to 25x on any execution miss. Wait for the $30.50–$33.00 entry zone.
Key Strengths
- FCF of $2.22 billion (~5.9% FCF yield at current market cap) is the most underappreciated asset — GAAP earnings of ~$0.60/share dramatically understate cash economics due to non-cash Actavis amortization; this FCF funds aggressive debt reduction (leverage ratio now below 3x EBITDA, targeting 2x by 2027) and demonstrates the business generates real cash despite depressed reported earnings
- Near-term EPS growth of 53.4% is 99.4% above the industry average of 26.76%, supported by genuine pipeline execution: FDA granted Priority Review for ecopipam in pediatric Tourette syndrome, UZEDY guidance raised, and specialty revenue targeting $3.7B at ~17% YoY growth — the 'Pivot to Growth' strategy is showing measurable results with news sentiment of 89.1/100 (10 of 13 articles positive)
- D/E of 1.60 is 76.6% below the industry average of 6.85, making Teva one of the most conservatively leveraged companies in a heavily indebted peer group; $3.655 billion cash provides additional liquidity buffer and the leverage ratio dropping below 3x EBITDA with a 2x target by 2027 confirms the deleveraging trajectory is on track
Key Concerns
- Valuation is the primary risk and has WORSENED marginally: P/E of 61.9x is now 117.1% above the industry average of 28.5x (up from 116.9% prior), PEG of 2.18 is 62.9% above peers at 1.34 (up from 62.4%), yet 5-year EPS CAGR of 5.5% remains 55.3% BELOW the industry average of 12.30% — Teva is the most expensive stock in the peer group relative to its long-term earnings power; if the branded pivot disappoints and the multiple compresses from 61x to 25x (still above industry average), the stock falls to approximately $15, a 60% loss from current levels; upside to analyst target has narrowed from 15.3% to 13.5% as the stock rose 1.6%
- Operating margin of 4.03% versus industry average of 14.43% (-72.1% gap) combined with revenue growth of -0.8% versus industry +6.84% confirms the turnaround is incomplete — the branded pivot must simultaneously grow revenue AND expand margins, and execution risk remains elevated; the Humana trial headline ('Humana agrees not to reference Teva's Israel ties at US drug trial') confirms ongoing litigation overhang that could generate unpredictable negative headlines
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
Teva's fundamentals present a bifurcated picture that has not materially changed since the prior report. Gross margin of 52.5% is in line with the industry average of 52.84%, confirming competitive product-level economics. However, operating margin of 4.03% is 72.1% below the industry average of 14.43% — a 48.5 percentage point compression from gross to operating margin that reflects heavy amortization of Actavis intangibles, restructuring charges, and SG&A burden. Net margin of 4.01% is 357% above the industry average of 0.88%, but this flatters Teva only because many peers are loss-making. ROE of 9.6% versus industry average of -13.51% looks strong in relative terms but is inadequate in absolute terms for a company with D/E of 1.60 — leverage should amplify ROE far higher, implying weak underlying asset returns of approximately 3-4%. FCF of $2.22 billion is the standout metric, suggesting GAAP earnings of ~$0.60/share dramatically understate cash economics due to non-cash Actavis amortization. Revenue growth of -0.8% versus industry average of +6.84% confirms the top line is contracting while peers grow. Forward EPS growth of 53.4% next year is 99.4% above the industry average of 26.76% — a genuine near-term catalyst — but the 5-year EPS CAGR of 5.5% is 55.3% below the industry average of 12.30%, revealing the near-term spike as a one-time normalization rather than structural acceleration. P/E of 61.9x on a 5.5% long-term grower with 4.0% net margins is extremely difficult to justify. Cash of $3.655 billion and D/E of 1.60 (76.6% below industry average of 6.85) provide meaningful financial stability.
News Sentiment
Teva Pharmaceutical is quietly becoming one of pharma's most compelling comeback stories — but investors who missed the early move may need to be patient before jumping in. The Israeli drugmaker, long known for its generic drug empire, is showing real signs that its ambitious transformation into a specialty pharmaceutical company is gaining traction. The biggest recent headline: the FDA granted Priority Review to Teva's ecopipam for pediatric Tourette syndrome — a significant regulatory milestone that fast-tracks the drug toward potential approval and signals the agency sees genuine unmet medical need. Priority Review status typically cuts the review timeline from 12 months to 6 months, potentially bringing a new revenue stream online sooner than expected. On the financial front, Teva's leverage ratio has dropped below 3x EBITDA — a milestone the company has been working toward for years after its debt-laden acquisition of Actavis Generics in 2016. Management is now targeting 2x by 2027, which would dramatically improve financial flexibility. The company also settled a patent dispute with Aurinia Pharmaceuticals over a kidney disease drug, removing one legal uncertainty from the picture. Meanwhile, a court ruling that Humana cannot reference Teva's Israel ties during a US drug trial clears another potential distraction. The stock is up 17% year-to-date, reflecting growing investor confidence in the 'Pivot to Growth' strategy. The question for new investors: at a P/E of nearly 62x, is the good news already priced in?
Risk Assessment
PRIMARY RISK — VALUATION COMPRESSION: At P/E of 61.9x on a 5.5% long-term EPS grower, any execution miss on the branded pivot (UZEDY ramp, ecopipam launch, specialty revenue target) could trigger multiple compression from 61x to 25x, implying a stock price of approximately $15 — a 60% loss from current levels. This is not a tail risk; it is the base case if growth disappoints. SECONDARY RISK — REVENUE CONTRACTION: Revenue growth of -0.8% versus industry +6.84% means the generics base is eroding faster than the specialty segment can compensate. If the specialty ramp stalls, the top line could deteriorate further, pressuring the earnings normalization thesis. TERTIARY RISK — LITIGATION OVERHANG: The Humana trial (Israel ties) and Aurinia patent settlement confirm ongoing legal complexity that could generate unexpected charges or negative headlines. MITIGATION: The $2.22B FCF provides a genuine floor — at $27.50 stop loss, the FCF yield would be approximately 8%+, which is a level where value investors would likely step in. The deleveraging trajectory (below 3x EBITDA, targeting 2x by 2027) reduces insolvency risk meaningfully. Position sizing at 3% limits portfolio impact if the multiple compression scenario materializes.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is TEVA a halal stock?
No, Teva Pharmaceutical Industries Limited (TEVA) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for TEVA?
Teva Pharmaceutical Industries Limited (TEVA) has a Plutrex AI rating of 58.5/100 with a Hold consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is TEVA a good investment?
According to Plutrex AI, TEVA has a Hold rating (58.5/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in TEVA?
US stocks like TEVA can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in TEVA?
Plutrex AI identifies the main risks for TEVA by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.